(NASDAQ:ONCY) Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 2, 2025 /PRNewswire/ -- Cancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain tumors, while...
Related Questions
How will the FDA approval of Modeyso affect ONCY's short‑term stock volatility and price target?
What is the potential market size and revenue upside from the approved aggressive malignancy indications compared to ONCY's existing pipeline and peers?
What are the reimbursement, manufacturing scalability, and regulatory rollout timelines that could influence ONCY's earnings outlook?